{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:31:41Z","timestamp":1784215901484,"version":"3.55.0"},"reference-count":71,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2022,5,24]]},"abstract":"<jats:p>Background: Parkinson\u2019s disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) present with similar movement disorder symptoms but distinct protein aggregates upon pathological examination. Objective: Discovery and validation of candidate biomarkers in parkinsonian disorders for differential diagnosis of subgroup molecular etiologies. Methods: Untargeted liquid chromatography (LC)-mass spectrometry (MS) proteomics was used for discovery profiling in cerebral spinal fluid (CSF) followed by LC-MS\/MS based multiple reaction monitoring for validation of candidates. We compared clinical variation within the parkinsonian cohort including PD subgroups exhibiting tremor dominance (TD) or postural instability gait disturbance and those with detectable leukocytes in CSF. Results: We have identified candidate peptide biomarkers and validated related proteins with targeted quantitative multiplexed assays. Dopamine-drug na\u00efve patients at first diagnosis exhibit reduced levels of signaling neuropeptides, chaperones, and processing proteases for packaging of self-aggregating peptides into dense core vesicles. Distinct patterns of biomarkers were detected in the parkinsonian disorders but were not robust enough to offer a differential diagnosis. Different biomarker changes were detected in male and female patients with PD. Subgroup specific candidate biomarkers were identified for TD PD and PD patients with leukocytes detected in CSF. Conclusion: PD, MSA, and PSP exhibit overlapping as well as distinct protein biomarkers that suggest specific molecular etiologies. This indicates common sensitivity of certain populations of selectively vulnerable neurons in the brain, and distinct therapeutic targets for PD subgroups. Our report validates a decrease in CSF levels of self-aggregating neuropeptides in parkinsonian disorders and supports the role of native amyloidogenic proteins in etiologies of neurodegenerative diseases.<\/jats:p>","DOI":"10.3233\/jpd-213031","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T13:56:15Z","timestamp":1646402175000},"page":"1169-1189","source":"Crossref","is-referenced-by-count":8,"title":["Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders"],"prefix":"10.1177","volume":"12","author":[{"given":"Shaochun","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"B\u00e4ckstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Forsgren","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Trupp","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-213031_ref1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-213031_ref2","doi-asserted-by":"crossref","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s disease and parkinsonism: Neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JPD-213031_ref3","doi-asserted-by":"crossref","first-page":"e2045","DOI":"10.1212\/WNL.0000000000006576","article-title":"Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study","volume":"91","author":"Backstrom","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JPD-213031_ref4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2990.1989.tb01147.x","article-title":"The significance of the Lewy body in the diagnosis of idiopathic Parkinson\u2019s disease","volume":"15","author":"Gibb","year":"1989","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-213031_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.3233\/JPD-213031_ref6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","article-title":"Consensus statement on the diagnosis of multiple system atrophy","volume":"163","author":"Gilman","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.3233\/JPD-213031_ref7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","article-title":"How stable are Parkinson\u2019s disease subtypes in de novo patients: Analysis of the PPMI cohort?","volume":"28","author":"Simuni","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-213031_ref8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.parkreldis.2019.06.017","article-title":"Motor phenotype classification in moderate to advanced PD in BioFIND study","volume":"65","author":"Luo","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-213031_ref9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nmeth.2767","article-title":"Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics","volume":"11","author":"Distler","year":"2014","journal-title":"Nat Methods"},{"key":"10.3233\/JPD-213031_ref10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s11306-015-0818-3","article-title":"Constrained randomization and multivariate effect projections improve information extraction and biomarker pattern discovery in metabolomics studies involving dependent samples","volume":"11","author":"Jonsson","year":"2015","journal-title":"Metabolomics"},{"key":"10.3233\/JPD-213031_ref11","doi-asserted-by":"crossref","first-page":"e78374","DOI":"10.1371\/journal.pone.0078374","article-title":"Transcriptional activation of the cholecystokinin gene by DJ-1 through interaction of DJ-1 with RREB1 and the effect of DJ-1 on the cholecystokinin level in mice","volume":"8","author":"Yamane","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JPD-213031_ref12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"Tamargo","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.3233\/JPD-213031_ref13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12031-017-0914-0","article-title":"Absence of carboxypeptidase E\/neurotrophic factor-alpha1 in knock-out mice leads to dysfunction of BDNF-TRKB signaling in hippocampus","volume":"62","author":"Xiao","year":"2017","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JPD-213031_ref14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fnagi.2020.00268","article-title":"Secreted chaperones in neurodegeneration","volume":"12","author":"Chaplot","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JPD-213031_ref15","doi-asserted-by":"crossref","first-page":"e0206478","DOI":"10.1371\/journal.pone.0206478","article-title":"Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research","volume":"13","author":"Schilde","year":"2018","journal-title":"PLoS One"},{"key":"10.3233\/JPD-213031_ref16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: What\u2019s the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-213031_ref17","doi-asserted-by":"crossref","first-page":"e09743","DOI":"10.7554\/eLife.09743","article-title":"APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses","volume":"4","author":"Fanutza","year":"2015","journal-title":"Elife"},{"key":"10.3233\/JPD-213031_ref18","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1093\/cercor\/bhaa025","article-title":"Lack of APP and APLP2 in GABAergic forebrain neurons impairs synaptic plasticity and cognition","volume":"30","author":"Mehr","year":"2020","journal-title":"Cereb Cortex"},{"key":"10.3233\/JPD-213031_ref19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.parkreldis.2017.01.016","article-title":"Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics","volume":"37","author":"Magdalinou","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-213031_ref20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-017-0266-6","article-title":"Glutaminyl cyclase activity correlates with levels of Abeta peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer\u2019s disease patients","volume":"9","author":"Bridel","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JPD-213031_ref21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease","volume":"72","author":"Backstrom","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-213031_ref22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JPD-140389","article-title":"Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson\u2019s disease","volume":"4","author":"Trupp","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-213031_ref23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000358430","article-title":"Pyroglutamate-amyloid-beta and glutaminyl cyclase are colocalized with amyloid-beta in secretory vesicles and undergo activity-dependent, regulated secretion","volume":"14","author":"Cynis","year":"2014","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JPD-213031_ref24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-2010-091651","article-title":"Converging pathways of chromogranin and amyloid metabolism in the brain","volume":"20","author":"Mattsson","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-213031_ref25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fnana.2018.00040","article-title":"Shaping synapses by the neural extracellular matrix","volume":"12","author":"Ferrer-Ferrer","year":"2018","journal-title":"Front Neuroanat"},{"key":"10.3233\/JPD-213031_ref26","doi-asserted-by":"crossref","first-page":"e0135365","DOI":"10.1371\/journal.pone.0135365","article-title":"High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer\u2019s disease in human cerebrospinal fluid","volume":"10","author":"Hendrickson","year":"2015","journal-title":"PLoS One"},{"key":"10.3233\/JPD-213031_ref27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.12688\/f1000research.15095.1","article-title":"Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer\u2019s disease progression","volume":"7","author":"Begcevic","year":"2018","journal-title":"F1000Res"},{"key":"10.3233\/JPD-213031_ref28","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1515\/cclm-2019-0428","article-title":"Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer\u2019s disease","volume":"57","author":"Lim","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.3233\/JPD-213031_ref29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-020-00388-2","article-title":"Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: A proteomic approach","volume":"15","author":"van Steenoven","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-213031_ref30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00401-007-0309-3","article-title":"Neuronal pentraxin II is highly upregulated in Parkinson\u2019s disease and a novel component of Lewy bodies","volume":"115","author":"Moran","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-213031_ref31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41586-020-2926-0","article-title":"Chemico-genetic discovery of astrocytic control of inhibition in vivo","volume":"588","author":"Takano","year":"2020","journal-title":"Nature"},{"key":"10.3233\/JPD-213031_ref32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.mcn.2011.12.002","article-title":"The role of NrCAM in neural development and disorders\u2013beyond a simple glue in the brain","volume":"49","author":"Sakurai","year":"2012","journal-title":"Mol Cell Neurosci"},{"key":"10.3233\/JPD-213031_ref33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.brainresrev.2004.01.003","article-title":"Oligodendrocyte myelin glycoprotein (OMgp): Evolution, structure and function","volume":"45","author":"Vourc\u2019h","year":"2004","journal-title":"Brain Res Brain Res Rev"},{"key":"10.3233\/JPD-213031_ref34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fnmol.2017.00202","article-title":"Amyloid-beta impairs vesicular secretion in neuronal and astrocyte peptidergic transmission","volume":"10","author":"Pla","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JPD-213031_ref35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41398-020-01112-w","article-title":"Neurotrophic factor-alpha1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: Comparison to BDNF","volume":"11","author":"Xiao","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JPD-213031_ref36","doi-asserted-by":"crossref","first-page":"e78617","DOI":"10.1371\/journal.pone.0078617","article-title":"Human factor H-related protein 2 (CFHR2) regulates complement activation","volume":"8","author":"Eberhardt","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JPD-213031_ref37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41467-020-15211-1","article-title":"NELL2-Robo3 complex structure reveals mechanisms of receptor activation for axon guidance","volume":"11","author":"Pak","year":"2020","journal-title":"Nat Commun"},{"key":"10.3233\/JPD-213031_ref38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.14348\/molcells.2017.2278","article-title":"A role of central NELL2 in the regulation of feeding behavior in rats","volume":"40","author":"Jeong","year":"2017","journal-title":"Mol Cells"},{"key":"10.3233\/JPD-213031_ref39","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"10.3233\/JPD-213031_ref40","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1073\/pnas.1715837115","article-title":"Transcription factor Pebbled\/RREB1 regulates injury-induced axon degeneration","volume":"115","author":"Farley","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-213031_ref41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41593-020-0690-y","article-title":"Epigenomic analysis of Parkinson\u2019s disease neurons identifies Tet2 loss as neuroprotective","volume":"23","author":"Marshall","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.3233\/JPD-213031_ref42","doi-asserted-by":"crossref","first-page":"baw100","DOI":"10.1093\/database\/baw100","article-title":"The harmonizome: A collection of processed datasets gathered to serve and mine knowledge about genes and proteins","volume":"2016","author":"Rouillard","year":"2016","journal-title":"Database (Oxford)"},{"key":"10.3233\/JPD-213031_ref43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1474-4422(06)70578-6","article-title":"Genome-wide genotyping in Parkinson\u2019s disease and neurologically normal controls: First stage analysis and public release of data","volume":"5","author":"Fung","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-213031_ref44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/bj3160671","article-title":"Apolipoprotein J and Alzheimer\u2019s amyloid beta solubility","volume":"316 (Pt 2)","author":"Matsubara","year":"1996","journal-title":"Biochem J"},{"key":"10.3233\/JPD-213031_ref45","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1096\/fj.06-7986com","article-title":"The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures","volume":"21","author":"Yerbury","year":"2007","journal-title":"FASEB J"},{"key":"10.3233\/JPD-213031_ref46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00401-002-0546-4","article-title":"Clusterin\/apolipoprotein J is associated with cortical Lewy bodies: Immunohistochemical study in cases with alpha-synucleinopathies","volume":"104","author":"Sasaki","year":"2002","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-213031_ref47","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.27949","article-title":"CLU rs11136000 promotes early cognitive decline in Parkinson\u2019s disease","volume":"35","author":"Sampedro","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213031_ref48","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/s41598-020-59414-4","article-title":"Cerebrospinal fluid proteomics implicates the granin family in Parkinson\u2019s disease","volume":"10","author":"Rotunno","year":"2020","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-213031_ref49","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.3233\/JPD-213031_ref50","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/pro.4025","article-title":"Interplay between tau and alpha-synuclein liquid-liquid phase separation","volume":"30","author":"Siegert","year":"2021","journal-title":"Protein Sci"},{"key":"10.3233\/JPD-213031_ref51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41557-020-0465-9","article-title":"alpha-Synuclein aggregation nucleates through liquid-liquid phase separation","volume":"12","author":"Ray","year":"2020","journal-title":"Nat Chem"},{"key":"10.3233\/JPD-213031_ref52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.devcel.2020.09.014","article-title":"Phase separation and neurodegenerative diseases: A disturbance in the force","volume":"55","author":"Zbinden","year":"2020","journal-title":"Dev Cell"},{"key":"10.3233\/JPD-213031_ref53","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3233\/JAD-191153","article-title":"Chromogranin A analysis in the differential diagnosis across Lewy body disorders","volume":"73","author":"Gmitterova","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-213031_ref54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/kjm2.12026","article-title":"Serum levels of chromogranins and secretogranins correlate with the progress and severity of Parkinson\u2019s disease","volume":"35","author":"Xu","year":"2019","journal-title":"Kaohsiung J Med Sci"},{"key":"10.3233\/JPD-213031_ref55","doi-asserted-by":"crossref","unstructured":"van Steenoven I , Noli B , Cocco C , Ferri GL , Oeckl P , Otto M , Koel-Simmelink MJA , Bridel C , van der Flier WM , Lemstra AW , Teunissen CE (2019) VGF peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Int J Mol Sci 20.","DOI":"10.3390\/ijms20194674"},{"key":"10.3233\/JPD-213031_ref56","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0196-9781(00)00271-0","article-title":"Secretoneurin: A functional neuropeptide in health and disease","volume":"21","author":"Wiedermann","year":"2000","journal-title":"Peptides"},{"key":"10.3233\/JPD-213031_ref57","doi-asserted-by":"crossref","first-page":"14872","DOI":"10.1523\/JNEUROSCI.4286-14.2015","article-title":"REST regulates non-cell-autonomous neuronal differentiation and maturation of neural progenitor cells via secretogranin II","volume":"35","author":"Kim","year":"2015","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-213031_ref58","doi-asserted-by":"crossref","first-page":"e0164689","DOI":"10.1371\/journal.pone.0164689","article-title":"VGF protein and its C-terminal derived peptides in amyotrophic lateral sclerosis: Human and animal model studies","volume":"11","author":"Brancia","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JPD-213031_ref59","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/acn3.745","article-title":"Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics","volume":"6","author":"van der Ende","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JPD-213031_ref60","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1038\/s41467-020-17405-z","article-title":"Multiscale causal networks identify VGF as a key regulator of Alzheimer\u2019s disease","volume":"11","author":"Beckmann","year":"2020","journal-title":"Nat Commun"},{"key":"10.3233\/JPD-213031_ref61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13024-020-0357-x","article-title":"VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice","volume":"15","author":"El Gaamouch","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-213031_ref62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0143-4179(95)90003-9","article-title":"Low cerebrospinal fluid concentrations of peptide histidine valine and somatostatin-28 in Alzheimer\u2019s disease: Altered processing of prepro-vasoactive intestinal peptide and prepro-somatostatin","volume":"29","author":"Yasuda","year":"1995","journal-title":"Neuropeptides"},{"key":"10.3233\/JPD-213031_ref63","doi-asserted-by":"crossref","first-page":"e28401","DOI":"10.7554\/eLife.28401","article-title":"Somatostatin binds to the human amyloid beta peptide and favors the formation of distinct oligomers","volume":"6","author":"Wang","year":"2017","journal-title":"Elife"},{"key":"10.3233\/JPD-213031_ref64","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.15190\/d.2017.9","article-title":"Functional amyloids and their possible influence on Alzheimer disease","volume":"5","author":"Lau","year":"2017","journal-title":"Discoveries (Craiova)"},{"key":"10.3233\/JPD-213031_ref65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12014-020-09276-9","article-title":"A comprehensive systematic review of CSF proteins and peptides that define Alzheimer\u2019s disease","volume":"17","author":"Pedrero-Prieto","year":"2020","journal-title":"Clin Proteomics"},{"key":"10.3233\/JPD-213031_ref66","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"10.3233\/JPD-213031_ref67","doi-asserted-by":"crossref","first-page":"118984","DOI":"10.1016\/j.bbamcr.2021.118984","article-title":"Combating deleterious phase transitions in neurodegenerative disease","volume":"1868","author":"Darling","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.3233\/JPD-213031_ref68","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-020-2942-0","article-title":"Assembly of synaptic active zones requires phase separation of scaffold molecules","volume":"588","author":"McDonald","year":"2020","journal-title":"Nature"},{"key":"10.3233\/JPD-213031_ref69","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.cell.2015.07.047","article-title":"A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation","volume":"162","author":"Patel","year":"2015","journal-title":"Cell"},{"key":"10.3233\/JPD-213031_ref70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nn.4529","article-title":"alpha-Synuclein promotes dilation of the exocytotic fusion pore","volume":"20","author":"Logan","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.3233\/JPD-213031_ref71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/jnc.14810","article-title":"The physiological role of alpha-synuclein and its relationship to Parkinson\u2019s disease","volume":"150","author":"Sulzer","year":"2019","journal-title":"J Neurochem"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-213031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:51:17Z","timestamp":1777611077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-213031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":71,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jpd-213031","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}